An observational study in Acute Myocardial Infarction (AMI), sponsored by Idoven 1903 S.L.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Idoven 1903 S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in ST Elevation Myocardial Infarction with a site in Spain — 4 open to participants now, 10 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Spain.
Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, this one is the 8th largest by enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, and was the 36th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →4 of the 41 studies in ST Elevation Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:
Hospital General Universitario Santa Lucia · Sites in Spain
Ages 18+
Fundación Interhospitalaria para la Investigación Cardiovascular FIC · Sites in Spain
Ages 18+
Hospital Universitario La Fe · Sites in Spain
Ages 18+
Hospital Arnau de Vilanova · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 489 is above the median of 340 across 298 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 450 across the 27 interventional studies, 495 across the 14 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 41 have an industry lead sponsor. The 10 most frequent:
Idoven 1903 S.L. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Idoven 1903 S.L. has 2 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in ST Elevation Myocardial Infarction with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT07780942Hospital General Universitario Santa LuciaSMARTwatch for the Diagnosis of ST-segment Elevation Myocardial Infarction in Patients With Chest Pain | 2027-02 |
| NCT07000266Fundacio Privada Mon Clinic BarcelonaThe RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack | 2027-05-16 |
| NCT07444957Fundación Interhospitalaria para la Investigación Cardiovascular FICSafety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease | 2027-07-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction (AMI).
The main objectives are to compare Willem™ performance to detect and triage ECG patterns associated with AMI compared with human ECG interpretation, and to assess the time periods for both approaches.
Delays in triage and diagnosis of patients presented with chest pain or other symptoms suggestive of Acute coronary syndrome (ACS) can be fatal. This study aims to improve those two aspects in acute ischemic disease care: reducing the delays to intervention and improving the accuracy of initial diagnosis, which are of paramount importance in cases of ACS, especially in ST-elevation myocardial infarction (STEMI). The former plays a critical role in minimizing in-hospital mortality rates, which have been shown to decrease proportionally with reduction of times to intervention. The latter relies on a correct interpretation of the ECG, first-line diagnostic tool in the assessment of patients with suspected ACS.
The current standard of care for ACS includes a 12-lead ECG that should be performed within the first 10 minutes from the first medical contact. The ECG must be interpreted by a qualified physician, who will alert the on-call cardiologist to confirm or not the activation of the "infarction code", based on the ECG and clinical presentation. Such activation will mainly entail immediate transfer of the patient to the nearest hospital with the possibility of emergency coronary angiography (if not present in the initial institution), and eventual percutaneous coronary intervention (PCI). Regarding the diagnosis of Acute Myocardial Infarction (AMI), an accurate and rapid interpretation of the first ECG is critical for the differential diagnosis between STEMI, NSTEMI or unstable angina; and follow the proper standard of care guidelines. The largest delays occurs between the first ECG and the transportation for the cardiac catheterization laboratory, which has prognostic implications.
In recent years, automatic digital tools based on artificial intelligence (AI) have been proposed as a solution to support physicians in the ECG interpretation, reducing their workload and time-to-diagnosis, suggesting the beneficial impact of AI-platforms for accurate diagnosis of AMI. In this setting, the AI-platforms should be able to automatically detect ECG patterns linked to unfavorable coronary anatomy and poor outcomes. It is also essential to have the capacity to identify more subtle ECG patterns, not obvious during physicians' interpretation, but indicating high-risk coronary anatomy. Additionally, the platform should assist the prediction of most severe coronary lesions, especially obstructive stenosis. This ability to detect coronary lesions could be useful in preventing unnecessary or premature activation of the catheterization laboratory, mainly in NSTEMI setting.
The ASSIST clinical study is a cross-sectional, multicenter study aiming to collect data to develop the Willem™ platform, an AI-based tool for ECG analysis. This plataform could improve the accuracy for AMI diagnosis, particularly the differentiation between STEMI and NSTEMI, and early identification of patients with Occlusion Myocardial Infarction (OMI).
Adult patients with suspected Acute Coronary Syndrome (ACS) presenting to the emergency department and subsequently referred for angiography at the Catheterization Laboratory of the participating sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device performance
Assessment of Willem™ diagnostic performance to detect Acute Myocardial Infarction (AMI) based on ECG analysis. The diagnostic performance metrics and their measurement units will be: * Accuracy, Sensitivity, and Specificity (%) * Positive Predictive Value (PPV) and Negative Predictive Value (NPV) (%) * F1-score (score from 0.0 to 1.0)
Time frame: At the time of enrolment and throughout the baseline visit (single study visit)
Time assessment
Assessment of the time needed for AMI diagnosis and for intervention (e.g. door-to-balloon time)
Time frame: At the time of enrolment and throughout the baseline visit (single study visit)
Plan to share: Undecided — Grouped data corresponding to the clinical study objectives may be published at the end of the study. All data collected throughout the study would be included, since all clinical variables are collected per the standard of care and all relate to the two study objectives.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Jun 2026, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Idoven 1903 S.L.